Payment overview · 2025
General Payments
$1,749.20
77 reported records · 13 companies
Healthcare provider profile · identity verified
Imran Sheriff, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RENO, NV · NPI 1659373678
Verified facts
What the public records show
CMS Open Payments records show Imran Sheriff, M.D. received $1,749.20 in general payments during 2025 across 77 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $712.10 | 40.7% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.22 | 13.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $171.65 | 9.8% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $163.10 | 9.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.37 | 6.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.83 | 5.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.26 | 2.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.52 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.10 | 2.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.93 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.35 | 1.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.88 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.89 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,749.20 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $321.01 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $236.19 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $217.10 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $192.04 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $171.65 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $170.59 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $156.26 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $88.35 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $88.35 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.14 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.26 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.10 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.06 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $6.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $6.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 144 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 43 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 188 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
188 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1339 | 402 |
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 663 | 221 |
| Lisinopril | Lisinopril | 659 | 199 |
| Losartan Potassium | Losartan Potassium | 571 | 172 |
| Metformin Hcl | Metformin Hcl | 554 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 500 | 165 |
| Omeprazole | Omeprazole | 411 | 134 |
| Gabapentin | Gabapentin | 368 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 332 | 114 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 318 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 305 | 128 |
| Alendronate Sodium | Alendronate Sodium | 298 | 92 |
| Trazodone Hcl | Trazodone Hcl | 283 | 95 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 264 | 92 |
| Simvastatin | Simvastatin | 243 | 74 |
| Jardiance | Empagliflozin | 211 | 68 |
| Carvedilol | Carvedilol | 205 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 41 |
| Furosemide | Furosemide | 190 | 72 |
| Ozempic | Semaglutide | 190 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 188 | 68 |
| Allopurinol | Allopurinol | 185 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 185 | 55 |
| Tradjenta | Linagliptin | 183 | 62 |
| Tramadol Hcl | Tramadol Hcl | 182 | 40 |
| Potassium Chloride | Potassium Chloride | 179 | 73 |
| Oxycodone Hcl | Oxycodone Hcl | 176 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 75 |
| Glimepiride | Glimepiride | 162 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 56 |
| Montelukast Sodium | Montelukast Sodium | 149 | 47 |
| Meloxicam | Meloxicam | 147 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 54 |
| Eliquis | Apixaban | 144 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 68 |
| Lovastatin | Lovastatin | 121 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 36 |
| Farxiga | Dapagliflozin Propanediol | 111 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 36 |
| Spironolactone | Spironolactone | 93 | 35 |
| Finasteride | Finasteride | 90 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 36 |
| Januvia | Sitagliptin Phosphate | 88 | 25 |
| Sertraline Hcl | Sertraline Hcl | 85 | 29 |
| Ezetimibe | Ezetimibe | 83 | 26 |
| Meclizine Hcl | Meclizine Hcl | 78 | 36 |
| Alprazolam | Alprazolam | 76 | 23 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 76 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 19 |
| Fenofibrate | Fenofibrate | 57 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 26 |
| Carisoprodol | Carisoprodol | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 15 |
| Xarelto | Rivaroxaban | 52 | 17 |
| Nystatin | Nystatin | 51 | 22 |
| Glipizide Er | Glipizide | 50 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 17 |
| Pregabalin | Pregabalin | 49 | 13 |
| Valsartan | Valsartan | 47 | 15 |
| Mirtazapine | Mirtazapine | 45 | 20 |
| Myrbetriq | Mirabegron | 45 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 43 |
| Linzess | Linaclotide | 43 | 17 |
| Ramipril | Ramipril | 43 | 13 |
| Terazosin Hcl | Terazosin Hcl | 43 | 14 |
| Famotidine | Famotidine | 41 | 17 |
| Prednisone | Prednisone | 41 | 33 |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Atenolol | Atenolol | 35 | 13 |
| Benazepril Hcl | Benazepril Hcl | 35 | 12 |
| Fenofibrate | Fenofibrate,micronized | 35 | 12 |
| Testosterone | Testosterone | 35 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Primidone | Primidone | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 29 | 12 |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 14 |
| Novolog Flexpen | Insulin Aspart | 28 | 12 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Colchicine | Colchicine | 20 | 14 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Risperidone | Risperidone | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,749.20 · 77 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, JOURNAVX, Kerendia, LINZESS, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, WATCHMAN FLX, Wegovy, ZAVZPRET, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error